Biological dose-escalated definitive radiation therapy in head and neck cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10773/18650 |
Resumo: | To compare treatment outcome of patients with head and neck (HN) tumours treated with definitive radiation therapy that, mainly owing to differences in the fractionation scheme used with simultaneous integrated boost techniques, resulted in a different biological dose. Methods: 181 patients with HN cancer, prescribed to about 70.2Gy in the primary tumour, were included in this study. Population cohort was divided into Group ,70 and Group $70 when the mean dose converted to a 2 Gy fractionation in the primary tumour was less or higher than 70.2Gy, respectively. The probability of local control (LC), locoregional control (LRC), disease-free survival (DFS) and overall survival (OS) was determined for both groups. The incidence of acute and late complications was compared between the two groups. Results: At 24 months for Groups ,70 and $70, LC was 83.2% and 87.5%, LRC was 79.5% and 81.6%, DFS was 56.3% and 66.8% and OS was 63.9% and 71.5% p5ns, respectively. The incidence of acute dysphagia, odynophagia and pain, and late mucositis was significantly higher in Group $70 than in Group ,70. The rate of xerostomia, dysphonia, radiodermatitis, alopecia, dental complications, hypoacusia and weight loss was comparable between the two groups. Conclusion: The biological dose escalation was safe, but an increase in the incidence of the acute side effects: dysphagia, odynophagia and pain and late mucositis, was obtained. Advances in knowledge: Despite the significant biological dose escalation, within the range of doses delivered to this cohort, no clear dose–response effect was observed |
id |
RCAP_4edd0bc2b945fd94784b7bf944d0b152 |
---|---|
oai_identifier_str |
oai:ria.ua.pt:10773/18650 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
|
spelling |
Biological dose-escalated definitive radiation therapy in head and neck cancerTo compare treatment outcome of patients with head and neck (HN) tumours treated with definitive radiation therapy that, mainly owing to differences in the fractionation scheme used with simultaneous integrated boost techniques, resulted in a different biological dose. Methods: 181 patients with HN cancer, prescribed to about 70.2Gy in the primary tumour, were included in this study. Population cohort was divided into Group ,70 and Group $70 when the mean dose converted to a 2 Gy fractionation in the primary tumour was less or higher than 70.2Gy, respectively. The probability of local control (LC), locoregional control (LRC), disease-free survival (DFS) and overall survival (OS) was determined for both groups. The incidence of acute and late complications was compared between the two groups. Results: At 24 months for Groups ,70 and $70, LC was 83.2% and 87.5%, LRC was 79.5% and 81.6%, DFS was 56.3% and 66.8% and OS was 63.9% and 71.5% p5ns, respectively. The incidence of acute dysphagia, odynophagia and pain, and late mucositis was significantly higher in Group $70 than in Group ,70. The rate of xerostomia, dysphonia, radiodermatitis, alopecia, dental complications, hypoacusia and weight loss was comparable between the two groups. Conclusion: The biological dose escalation was safe, but an increase in the incidence of the acute side effects: dysphagia, odynophagia and pain and late mucositis, was obtained. Advances in knowledge: Despite the significant biological dose escalation, within the range of doses delivered to this cohort, no clear dose–response effect was observedBritish Institute of Radiology2017-10-26T10:19:50Z2017-01-01T00:00:00Z2017info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10773/18650eng0007-128510.1259/bjr.20160477Costa Ferreira, B.Sá-Couto, P.Khouri, L.Lopes, M. C.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-17T03:47:50ZPortal AgregadorONG |
dc.title.none.fl_str_mv |
Biological dose-escalated definitive radiation therapy in head and neck cancer |
title |
Biological dose-escalated definitive radiation therapy in head and neck cancer |
spellingShingle |
Biological dose-escalated definitive radiation therapy in head and neck cancer Costa Ferreira, B. |
title_short |
Biological dose-escalated definitive radiation therapy in head and neck cancer |
title_full |
Biological dose-escalated definitive radiation therapy in head and neck cancer |
title_fullStr |
Biological dose-escalated definitive radiation therapy in head and neck cancer |
title_full_unstemmed |
Biological dose-escalated definitive radiation therapy in head and neck cancer |
title_sort |
Biological dose-escalated definitive radiation therapy in head and neck cancer |
author |
Costa Ferreira, B. |
author_facet |
Costa Ferreira, B. Sá-Couto, P. Khouri, L. Lopes, M. C. |
author_role |
author |
author2 |
Sá-Couto, P. Khouri, L. Lopes, M. C. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Costa Ferreira, B. Sá-Couto, P. Khouri, L. Lopes, M. C. |
description |
To compare treatment outcome of patients with head and neck (HN) tumours treated with definitive radiation therapy that, mainly owing to differences in the fractionation scheme used with simultaneous integrated boost techniques, resulted in a different biological dose. Methods: 181 patients with HN cancer, prescribed to about 70.2Gy in the primary tumour, were included in this study. Population cohort was divided into Group ,70 and Group $70 when the mean dose converted to a 2 Gy fractionation in the primary tumour was less or higher than 70.2Gy, respectively. The probability of local control (LC), locoregional control (LRC), disease-free survival (DFS) and overall survival (OS) was determined for both groups. The incidence of acute and late complications was compared between the two groups. Results: At 24 months for Groups ,70 and $70, LC was 83.2% and 87.5%, LRC was 79.5% and 81.6%, DFS was 56.3% and 66.8% and OS was 63.9% and 71.5% p5ns, respectively. The incidence of acute dysphagia, odynophagia and pain, and late mucositis was significantly higher in Group $70 than in Group ,70. The rate of xerostomia, dysphonia, radiodermatitis, alopecia, dental complications, hypoacusia and weight loss was comparable between the two groups. Conclusion: The biological dose escalation was safe, but an increase in the incidence of the acute side effects: dysphagia, odynophagia and pain and late mucositis, was obtained. Advances in knowledge: Despite the significant biological dose escalation, within the range of doses delivered to this cohort, no clear dose–response effect was observed |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-10-26T10:19:50Z 2017-01-01T00:00:00Z 2017 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10773/18650 |
url |
http://hdl.handle.net/10773/18650 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
0007-1285 10.1259/bjr.20160477 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
British Institute of Radiology |
publisher.none.fl_str_mv |
British Institute of Radiology |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1777303529735585792 |